Literature DB >> 4198109

The association of respiratory infection, recurrent hematuria, and focal glomerulonephritis with activation of the complement system in the cold.

N K Day, H Geiger, R McLean, J Resnick, A Michael, R A Good.   

Abstract

The study of the activation of C3, C5, and C7 associated with the conversion of C3 in the serum of a 9-yr old girl after incubation at 0 degrees C for 6-8 h without utilization of C1, C4, and C2 is described. The patient has upper respiratory infections associated with recurrent gross hematuria, focal glomerulonephritis, and transient renal insufficiency. Histological lesions demonstrated the presence of B1c globulin IgA and properdin in the glomeruli. The activation of complement (C) in the cold requires the patient's IgA. Removal of IgA from the serum by immunoadsorption prevents activation and conversion of C3. Bactericidal and phagocytic activity is also impaired after incubation. C3 proactivator (C3PA) level is reduced before and after incubation. Properdin level drops after incubation. These findings suggest that the activation of C3 which is demonstrable in vitro may be a continuous process in vivo.

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4198109      PMCID: PMC302445          DOI: 10.1172/JCI107351

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  18 in total

1.  A new supporting medium for preparative electrophoresis.

Authors:  H J MULLER-EBERHARD
Journal:  Scand J Clin Lab Invest       Date:  1960       Impact factor: 1.713

2.  Quantitative studies on the bactericidal actions of serum and complement. I. A rapid photometric growth assay for bactericidal activity.

Authors:  L H MUSCHEL; H P TREFFERS
Journal:  J Immunol       Date:  1956-01       Impact factor: 5.422

3.  The properdin system and immunity. I. Demonstration and isolation of a new serum protein, properdin, and its role in immune phenomena.

Authors:  L PILLEMER; L BLUM; I H LEPOW; O A ROSS; E W TODD; A C WARDLAW
Journal:  Science       Date:  1954-08-20       Impact factor: 47.728

4.  Lupus-erythematosus-like syndrome with a familial defect of complement.

Authors:  B Moncada; N K Day; R A Good; D B Windhorst
Journal:  N Engl J Med       Date:  1972-03-30       Impact factor: 91.245

5.  Functional relationship of factor B in the properdin system to C3 proactivator of human serum.

Authors:  I Goodkofsky; I H Lepow
Journal:  J Immunol       Date:  1971-10       Impact factor: 5.422

6.  Immunochemical quantitation of antigens by single radial immunodiffusion.

Authors:  G Mancini; A O Carbonara; J F Heremans
Journal:  Immunochemistry       Date:  1965-09

7.  Methods for the separation, purification and measurement of nine components of hemolytic complement in guinea-pig serum.

Authors:  R A Nelson; J Jensen; I Gigli; N Tamura
Journal:  Immunochemistry       Date:  1966-03

8.  Complement activity and inflammatory neutrophil exudation in man. Studies in patients with glomerulonephritis, essential hypocomplementemia and agammaglobulinemia.

Authors:  H Gewurz; A R Page; R J Pickering; R A Good
Journal:  Int Arch Allergy Appl Immunol       Date:  1967

9.  C2 deficiency. Development of lupus erythematosus.

Authors:  N K Day; H Geiger; R McLean; A Michael; R A Good
Journal:  J Clin Invest       Date:  1973-07       Impact factor: 14.808

10.  Deficiency of C1r in human serum. Effects on the structure and function of macromolecular C1.

Authors:  R J Pickering; G B Naff; R M Stroud; R A Good; H Gewurz
Journal:  J Exp Med       Date:  1970-04-01       Impact factor: 14.307

View more
  10 in total

1.  Isolated glomerulonephritis with mesangial IgA deposits.

Authors:  J G Sissons; D F Woodrow; J R Curtis; D J Evans; P E Gower; J C Sloper; D K Peters
Journal:  Br Med J       Date:  1975-09-13

2.  Cold-dependent activation of complement: recognition, assessment, and mechanism.

Authors:  K P Mathews; R A Mentyka; S L Chambers; T E Hugli; J H Herschbach; B L Zuraw
Journal:  J Clin Immunol       Date:  1992-09       Impact factor: 8.317

3.  Circulating immune complexes detected by 125I-Clq deviation test in sera of cancer patients.

Authors:  H Teshima; H Wanebo; C Pinsky; N K Day
Journal:  J Clin Invest       Date:  1977-06       Impact factor: 14.808

4.  The secretory immune system and renal disease.

Authors:  R S Dobrin; F E Knudson; A F Michael
Journal:  Clin Exp Immunol       Date:  1975-08       Impact factor: 4.330

5.  Circulating immune complexes in sera of children with neuroblastoma: correlation with stage of disease.

Authors:  W E Brandeis; L Helson; Y Wang; R A Good; N K Day
Journal:  J Clin Invest       Date:  1978-12       Impact factor: 14.808

6.  Glomerulonephritis with mesangial deposits of IgA unassociated with systemic disease.

Authors:  A Katz; B J Underdown; J O Minta; I H Lepow
Journal:  Can Med Assoc J       Date:  1976-02-07       Impact factor: 8.262

7.  Idiopathic mesangial IgA-glomerulonephritis in childhood Description of 19 pediatric cases and review of the literature.

Authors:  D Michalk; R Waldherr; H P Seelig; H P Weber; K Schärer
Journal:  Eur J Pediatr       Date:  1980-06       Impact factor: 3.183

8.  Evidence for immune complexes involving anti-lymphocyte antibodies associated with hypocomplementaemia in chronic lymphocytic leukaemia (CLL).

Authors:  N K Day; J B Winfield; T Gee; R Winchester; H Teshima; H G Kunkel
Journal:  Clin Exp Immunol       Date:  1976-11       Impact factor: 4.330

9.  A serum factor in chronic hypocomplementemic hephritis distinct from immunoglobulins and activating the alternate pathway of complement.

Authors:  E H Vallota; O Götze; H L Spiegelberg; J Forristal; C D West; H J Müller-Eberhard
Journal:  J Exp Med       Date:  1974-05-01       Impact factor: 14.307

Review 10.  Title IgA Nephropathy and Oral Bacterial Species Related to Dental Caries and Periodontitis.

Authors:  Yasuyuki Nagasawa; Taro Misaki; Seigo Ito; Shuhei Naka; Kaoruko Wato; Ryota Nomura; Michiyo Matsumoto-Nakano; Kazuhiko Nakano
Journal:  Int J Mol Sci       Date:  2022-01-10       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.